Definitive Healthcare (NASDAQ:DH) Given “Hold” Rating at Needham & Company LLC

Definitive Healthcare (NASDAQ:DH)‘s stock had its “hold” rating restated by investment analysts at Needham & Company LLC in a research report issued on Friday,Benzinga reports.

Other analysts also recently issued reports about the stock. BTIG Research assumed coverage on shares of Definitive Healthcare in a research report on Tuesday, September 17th. They issued a “buy” rating and a $7.00 target price on the stock. Stifel Nicolaus decreased their target price on shares of Definitive Healthcare from $9.50 to $7.50 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Morgan Stanley dropped their price target on Definitive Healthcare from $9.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 6th. JPMorgan Chase & Co. downgraded Definitive Healthcare from a “neutral” rating to an “underweight” rating and cut their price target for the stock from $7.00 to $5.00 in a research note on Wednesday, July 31st. Finally, Robert W. Baird lowered their price objective on Definitive Healthcare from $6.00 to $5.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $5.81.

Definitive Healthcare Stock Up 0.2 %

DH stock opened at $4.31 on Friday. The company has a market capitalization of $508.30 million, a price-to-earnings ratio of -1.24, a price-to-earnings-growth ratio of 5.95 and a beta of 1.33. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.40 and a current ratio of 2.40. The business’s 50 day moving average price is $4.37 and its two-hundred day moving average price is $5.04. Definitive Healthcare has a fifty-two week low of $3.19 and a fifty-two week high of $10.62.

Definitive Healthcare (NASDAQ:DH) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.09 earnings per share for the quarter, hitting the consensus estimate of $0.09. The company had revenue of $63.70 million for the quarter, compared to analysts’ expectations of $63.19 million. Definitive Healthcare had a positive return on equity of 0.98% and a negative net margin of 156.65%. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.08 earnings per share. As a group, analysts forecast that Definitive Healthcare will post 0.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Definitive Healthcare

Hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Definitive Healthcare by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 4,535,377 shares of the company’s stock worth $36,600,000 after buying an additional 67,068 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Definitive Healthcare by 28.3% during the second quarter. Massachusetts Financial Services Co. MA now owns 4,426,420 shares of the company’s stock valued at $24,168,000 after purchasing an additional 976,279 shares during the last quarter. Millennium Management LLC bought a new position in Definitive Healthcare during the second quarter valued at approximately $9,283,000. Granite Investment Partners LLC boosted its holdings in Definitive Healthcare by 22.5% in the second quarter. Granite Investment Partners LLC now owns 884,872 shares of the company’s stock worth $4,831,000 after purchasing an additional 162,432 shares during the last quarter. Finally, 272 Capital LP bought a new stake in Definitive Healthcare in the 2nd quarter worth approximately $3,480,000. 98.67% of the stock is currently owned by hedge funds and other institutional investors.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.